Lykos Therapeutics Reshuffles Board of Directors Following FDA Rejection of Midomafetamine Capsules

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.